FORM 4

Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b)

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person BOGER JOSHUA S						VERTEX PHARMACEUTICALS INC / MA [VRTX]								(Check all applicable) X Director Officer (give t			g Pers	10% Ow Other (s	ner
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 08/13/2008								X Officer (give title below) President & CEO					
130 WAVERLY STREET (Street) CAMBRIDGE MA 02139					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					1
(City) (State) (Zip)																			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day)				ction	on 2A. Deemed Execution Date,			3. Transa Code (8)	action	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5. Amour Securitie Beneficia		nt of es ally Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	tion(s)			
Common Stock 08/13/					/2008	308			M		12,400	A	\$10.	.19	1,10	07,444		D	
Common Stock 08/13.					/2008	2008			S ⁽¹⁾		9,400	D	\$28.9	7(2)(4)	1,098,0			D	
Common Stock 08/13/20					/2008	08			S ⁽¹⁾		3,000	D	\$29.7	5(3)(4)	1,09	5,044		D	
Common Stock															12	,445		I 4	401(k)
Common Stock														207,500				Shares in rust ⁽⁵⁾	
			Table II								posed of, convertil				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any	A. Deemed execution Date, f any Month/Day/Year)		ction Instr.			6. Date Exerc Expiration Da (Month/Day/\)		ate	7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		ty De Si	Price of erivative ecurity nstr. 5)		Ov Fo Di or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amou or Numb of Share	er					
Stock	\$10.19	08/13/2008			M			12,400	(6	5)	09/16/2008	Commor	12,40	00	\$0	49,978	3	D	

Explanation of Responses:

- $1.\ Transaction for sales of common stock made pursuant to Dr.\ Boger's company approved trading plan established under Rule 10b5-1.$
- 2. Open market sales reported on this line occurred at a weighted average price of \$28.97 (range \$28.54 to \$29.53).
- 3. Open market sales reported on this line occurred at a weighted average price of \$29.75 (range \$29.54 to \$30.17).
- 4. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- $5.\ Shares\ held\ in\ trust\ for\ Dr.\ Boger's\ children.\ Dr.\ Boger\ disclaims\ beneficial\ ownership\ of\ such\ shares.$
- 6. Fully vested.

Remarks:

Kenneth S. Boger, Attorney-In-Fact

08/14/2008

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.